Drugs / OLITIGALTIN
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04473053 | Jul 2020 → Apr 2025 | COVID-19 | University of Edinburgh | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03832946 | Feb 2019 → May 2023 | idiopathic pulmonary fibrosis | Galecto Biotech AB | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02257177 Comparator | Sep 2014 → Dec 2016 | idiopathic pulmonary fibrosis | Galecto Biotech AB | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OLITIGALTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297442 ↗ |
| Known as | GB0139 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03832946 ↗ |
| Known as | Olitigaltina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297442 ↗ |
| Known as | Olitigaltine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297442 ↗ |
| Known as | TD139 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02257177 ↗ |
| Action | Inhibit | “TD139 is a novel and potent small-molecule inhibitor of Gal-3.” PMID 33214209 ↗ May 20211“Galectin-3 inhibitor” CHEMBL4297442 ↗ |
| Modality | Small molecule | “TD139 is a novel and potent small-molecule inhibitor of Gal-3.” PMID 33214209 ↗ May 2021 |
| Route | Inhaled | “inhaled TD139 in 36 healthy subjects and 24 patients with IPF” PMID 33214209 ↗ May 2021 |
| Target | LGALS3 | “Galectin-3 inhibitor” CHEMBL4297442 ↗ |